Anti-CES2 antibody [EPR14856],Abcam,AB184957
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
WB, IHC-P
Platform ID
BAB135256868
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs (PubMed : 9169443). Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine (PubMed : 9169443). Hydrolyzes aspirin, substrates with large alcohol group and small acyl group and endogenous lipids such as triacylglycerol (PubMed : 28677105). Converts monoacylglycerides to free fatty acids and glycerol. Hydrolyzes of 2-arachidonoylglycerol and prostaglandins (PubMed : 21049984). See full target information CES2
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.